Skip to main content
Clinical Trials/NL-OMON47969
NL-OMON47969
Not yet recruiting
Not Applicable

PROSPECTIVE, TRIAL EVALUATING THE SAFETY AND EFFECTIVENESS OF THE INTERSCOPE ENDOROTOR® RESECTION SYSTEM FOR DIRECT ENDOSCOPIC NECROSECTOMY OF WALLED OFF PANCREATIC NECROSIS - ENDOROTOR DEN TRIA

Interscope Medical, Inc.0 sites5 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
encapsulated pancreatic necrosis
Sponsor
Interscope Medical, Inc.
Enrollment
5
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Interscope Medical, Inc.

Eligibility Criteria

Inclusion Criteria

  • 1\. Subjects who are \>22; inclusive of males and females.
  • 2\. Patients with symptomatic pancreatic necrosis due to acute pancreatitis that have an indication
  • to undergo endoscopic necrosectomy after having undergone EUS\-guided drainage
  • 3\. Imaging suggestive of greater than or equal to 30% necrotic material
  • 4\. Walled off pancreatic necrosis size \*6 cm and \*22cm
  • 5\. Subject can tolerate repeated endoscopic procedures
  • 6\. Subject capable of giving informed consent.
  • 7\. Subjects with the ability to understand the requirements of the study, who have provided written informed
  • consent, and who are willing and able to return for the required follow\-up assessments through 21 (\+/\- 7\)
  • days, as indicated.

Exclusion Criteria

  • 1\. Subject unable to give informed consent.
  • 2\. Subject is unwilling to return for repeated endoscopies.
  • 3\. Documented Pseudoaneurysm \> 1cm within the WOPN
  • 4\. Intervening gastric varices or unavoidable blood vessels within the access tract (visible using
  • endoscopy or endoscopic ultrasound).
  • 5\. Dual antiplatelet therapy or therapeutic anticoagulation that cannot be withheld for the procedure
  • 6\. Any condition that in the opinion of the investigator would create an unsafe clinical situation that would not
  • allow the patient to safely undergo an endoscopic procedure (lack of medical clearance).
  • 7\. Pregnant or lactating women or women of childbearing potential who do not employ a reliable method of
  • contraception as judged by the Investigator, and/or are not willing to use reliable contraception for the

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
To Study the Safety and Effectiveness of New LASER Treatment in Glaucoma patientsHealth Condition 1: H402- Primary angle-closure glaucoma
CTRI/2019/12/022443ALeyeGN Technologies LLC
Active, not recruiting
Not Applicable
A Prospective Trial to Assess the Safety and Performance of the Spinal Modulation Neurostimulator System in the Treatment of Chronic PaiChronic Neuropathic PainAnaesthesiology - Pain managementMusculoskeletal - Other muscular and skeletal disorders
ACTRN12610001062011Spinal Modulation30
Completed
Not Applicable
A Prospective Trial to Assess the Safety and Performance of the Spinal Modulation Neurostimulator System in the Treatment of Chronic PaiChronic intractable pain
NL-OMON36763Spinal Modulation35
Active, not recruiting
Phase 1
Value of inhaled treatment with Aztreonam lysine in bronchiectasis- VITAL- BEBronchiectasisMedDRA version: 20.1Level: PTClassification code 10006445Term: BronchiectasisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2018-001590-24-GBniversity of Dundee100
Recruiting
Not Applicable
Prospective evaluation of the safety and efficacy of MR-guided single-fraction stereotactic ablative radiotherapy for unresectable primary or secondary liver tumors - SINGLE SHOT LIVERC22C78.7Malignant neoplasm of liver and intrahepatic bile ductsSecondary malignant neoplasm of liver and intrahepatic bile duct
DRKS00027117Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Klinikum Grosshadern der LMU München35